Comparison of the efficacy of low‐intensity shock wave therapy and its combination with platelet‐rich plasma in patients with erectile dysfunction

Geyik, Serdar

doi:10.1111/and.14197

Cited by 14 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Geyik (2021) pointed out that the combination treatment of low‐intensity shock wave therapy with cavernous PRP injections is safe for ED patients and is also effective in prolonging the intravaginal ejaculatory latency time. Additionally, Taş et al.…”

Section: Discussionmentioning

confidence: 99%

“…In this context, the platelet‐rich plasma (PRP) therapy is a platelet‐based treatment that is prepared by the centrifugation of the patient's blood (Drury et al., 2021). Lately, PRP has been presented as a preference in various medicinal specialties such as otolaryngology, plastic surgery, urology and orthopaedics to deliver the regenerative capability to the tissues by introduction of autologous plasma with amplified platelet concentrations that far exceed that of normal blood levels (Everts et al, 2020; Geyik, 2021; Wu et al, 2016a).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of the intracavernosal injection platelet‐rich plasma in addition to daily oral tadalafil intake in diabetic patients with erectile dysfunction non‐responding to on‐demand oral PDE5 inhibitors

et al. 2022

View full text Add to dashboard Cite

This study aimed to evaluate the effectiveness of ICI of platelet‐rich plasma (PRP) in addition to daily oral tadalafil intake in diabetic erectile dysfunction (ED) patients non‐responding to PDE5 inhibitors. Overall, 48 patients complaining of ED non‐responding to on‐demand PDE5 inhibitors were allocated into 2 equal groups, diabetics and non‐diabetics that were given a daily dose of 5 mg tadalafil plus vardenafil 20 mg on demand during the study besides being subjected to 3 doses of ICI of PRP, 4 weeks apart. Responses to on‐demand PDE5 inhibitors, International index of erectile function‐5 (IIEF‐5) score, erection hardness scores (EHS) and pharmaco‐dynamic duplex studies were assessed. After PRP injections, 33% and 50% of cases were satisfied with on‐demand PDE5 inhibitors, respectively, whereas 41% and 66% of them showed improved EHS response. Compared with baseline scores, the mean IIEF‐5 scores were significantly improved after PRP therapy in the diabetic ED group (12.1 vs. 8.04, p = 0.003) as well as in the non‐diabetic ED group (14.8 vs. 10.2, p = 0.001) linked to pharmaco‐penile duplex readings. Both good and fair diabetic control exhibited significant responses to ICI therapy of PRP compared with bad controlled cases. The significant improvement included; the IIEF‐5 score increase (86.7%, 126% vs. 16.1%), improved EHS as well as penile duplex readings. Baseline HbA1C demonstrated a significant negative correlation with IIEF‐5 score before (p = 0.019) and after PRP therapy (p = 0.002) respectively. It could be concluded that ICI of PRP could be an effective therapy for treating ED patients non‐responding to on‐demand oral PDE5 treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Assessment of the intracavernosal injection platelet‐rich plasma in addition to daily oral tadalafil intake in diabetic patients with erectile dysfunction non‐responding to on‐demand oral PDE5 inhibitors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…No major adverse events Small sample size, no control group. PRP injections were given randomly (multiple times if requested) Geyik [ 21 ] 2021 Retrospective Cohort Study Group 1: 93 patients Mean age (SD): 51.23 (± 11.36) years Group 2: 91 patients Mean age (SD): 46.9 (± 11.89) years Inclusion criteria: Vasculogenic ED Patients with < 26 IIEF-EF score after use of daily 5 mg of tadalafil for at least 3 months Exclusion criteria: glycated haemoglobin > 7 ng/ml; hypogonadism (testosterone < 4 ng/ml); non-adjusted cardiac and antihypertensive medications with consultations; pelvic surgery; degenerative neurological disorders, not followed up; data unavailability Group 1: Li-SWT, Group 2: Li-SWT with PRP Autologous PRP self-gelled and citrated (Ycellbio PRP). Sample was centrifuged at 3.700 (RPM) Each PRP injection (3–4 ml) was administered 10–14 days apart three times in one course.…”

Section: Evidence Synthesismentioning

confidence: 99%

Platelet-rich plasma therapy in erectile dysfunction and Peyronie’s disease: a systematic review of the literature

Asmundo,

Durukan,

von Rohden

et al. 2024

World J Urol

View full text Add to dashboard Cite

Purpose Platelet-rich plasma (PRP) as a regenerative therapy has gained interest in the field of andrology for the treatment of erectile dysfunction (ED) and Peyronie’s disease (PD). This systematic review aims to critically evaluate the current evidence on the use of PRP for these conditions. Methods We performed a systematic literature search according to the PRISMA guidelines using PubMed and Scopus databases in December 2023. Studies were included if they evaluated the effect of PRP therapy for ED or PD in humans. Results We identified 164 articles, 17 of which were included, consisting of 11 studies on ED, 5 studies on PD, and 1 study on both. We included four randomized controlled trials, 11 prospective cohort studies, and three retrospective cohort studies including a total of 1099 patients. The studies on ED and PD generally showed small to moderate benefits with mild and transient side effects and no major adverse events were reported. General limitations included variations in PRP protocols, small sample sizes, short follow-up periods, and lack of control groups except in the three randomized trials on ED and the one on PD. Conclusion The literature on PRP therapy in andrology is limited and difficult to interpret due to variations in protocols and methodological drawbacks. Further research is necessary to determine the optimal preparation and treatment protocols for PRP therapy and clarify its effectiveness in andrology.

show abstract

“…The study found that the combination therapy significantly improved erectile function and penile blood flow and resulted in the regeneration of penile tissue. The combination of Li-ESWT with PRP therapy has also been proposed as a potential treatment for ED [74] [73].…”

Section: Expert Opinionmentioning

confidence: 99%

Recent advances in stem cell therapy for erectile dysfunction: a narrative review

Wang

Gao

Zheng

et al. 2023

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction: While phosphodiesterase type 5 inhibitors (PDE5is) and others are used to treat Erectile dysfunction (ED), many patients are either unresponsive or resistant to it. Stem cell therapy (SCT) is a promising alternative approach. Numerous preclinical trials have demonstrated improved erectile function in animal models using SCT, although the number of clinical trials investigating SCT for men with ED is limited. Nonetheless, findings from human clinical trials suggest that SCT may be a useful treatment option.Areas covered: Biomedical literature, including PubMed, ClinicalTrials.gov, and European Union Clinical Trails Registry, were analyzed to summarize and synthesize information on stem cell therapy for ED in this narrative review. The achievements in preclinical and clinical evaluations are presented and critically analyzed.Expert opinion: SCT has demonstrated some benefits in improving erectile function, while further studies are urgently needed. Such studies would provide valuable insights into the optimal use of stem cell therapy and its potential as a therapeutic option for ED. Taking advantage of different mechanisms of action involved in various regenerative therapies, combination therapies such as SCT and low-energy shock waves or platelet-rich plasma may provide a more effective therapy and warrant further research.

show abstract

Comparison of the efficacy of low‐intensity shock wave therapy and its combination with platelet‐rich plasma in patients with erectile dysfunction

Cited by 14 publications

References 20 publications

Assessment of the intracavernosal injection platelet‐rich plasma in addition to daily oral tadalafil intake in diabetic patients with erectile dysfunction non‐responding to on‐demand oral PDE5 inhibitors

Assessment of the intracavernosal injection platelet‐rich plasma in addition to daily oral tadalafil intake in diabetic patients with erectile dysfunction non‐responding to on‐demand oral PDE5 inhibitors

Platelet-rich plasma therapy in erectile dysfunction and Peyronie’s disease: a systematic review of the literature

Recent advances in stem cell therapy for erectile dysfunction: a narrative review

Contact Info

Product

Resources

About